Table 3.
Secondary outcomes.
| Patient Subgroups | COVID-19-Associated Hospitalization or Death |
p-Value; UVA OR (95% CI), p-Value; MVA OR (95% CI), p-Value | |
|---|---|---|---|
| Yes n (%) |
No n (%) |
||
| COVID-19 vaccine received * | p = 0.759; 0.729 (0.223, 2.382), p = 0.6; 0.929 (0.222, 3.886), p = 0.919 | ||
| Yes (n = 52) | 17/23 (74) | 35/45 (78) | |
| No (n = 15) | 6/23 (26) | 9/45 (20) | |
| COVID-19 mAb treatment received | p = 0.070; 0.338 (0.112, 1.013), p = 0.053; 0.324 (0.096, 1.098), p = 0.07 | ||
| Yes (n = 29) | 6/23 (26) | 23/45 (51) | |
| No (n = 39) | 17/23 (74) | 22/45 (49) | |
| Anti-CD20 mAb or BTKi-containing regimen φ |
p = 0.907 1.5 (0.386, 5.825), p = 0.558; 2.899 (0.459, 18.319), p = 0.258 1 (0.15, 6.671), p = 1; 1.492 (0.178, 12.489), p = 0.712 0.857 (0.239, 3.079), p = 0.813; 1.571 (0.281, 8.775), p = 0.607 |
||
| Anti-CD20 mAb monotherapy (n = 14) | 6/23 (26) | 8/45 (18) | |
| BTKi monotherapy (n = 6) | 2/23 (9) | 4/45 (9) | |
| Anti-CD20 mAb + chemotherapy (n = 20) | 6/23 (26) | 14/45 (31) | |
| All others (ref) (n = 25) | 8/23 (35) | 17/45 (38) | |
| Lymphoma diagnosis |
p = 1 1.148 (0.327, 4.028), p = 0.829, 1.789 (0.321, 9.961), p = 0.507 1.240 (0.261, 5.891), p = 0.787; 1.157 (0.167,8.03), p = 0.883 |
||
| CLL/SLL (n = 14) | 5/23 (22) | 9/45 (20) | |
| HL/TCL (n = 8) | 3/23 (13) | 5/45 (11) | |
| All others (ref) (n = 46) | 15/23 (65) | 31/45 (69) | |
| Anticancer treatment in previous 6 months |
p = 0.481 1.368 (0.379, 4.944), p = 0.632; 0.725 (0.143, 3.68), p = 0.68976 0.625 (0.144, 2.718), p = 0.531; 0.366 (0.063, 2.12), p = 0.2622 |
||
| Yes (n = 32) | 13/23 (57) | 19/45 (42) | |
| No (n = 21) | 5/23 (9) | 16/45 (36) | |
| All others (ref) (n = 15) | 5/23 (9) | 10/45 (22) | |
UVA—univariate analysis; OR—odds ratio; CI—confidence interval; MVA—multivariate analysis; mAb—monoclonal antibody; BTKi—Bruton’s tyrosine kinase inhibitor; CLL—chronic lymphocytic leukemia; SLL—small lymphocytic lymphoma; HL—Hodgkin’s lymphoma; TCL—T-cell lymphomas. * One patient with unknown COVID-19 vaccination status; φ 3 patients with unknown treatment history with an anti-CD20 mAb or BTKi.